Michael TRAUNER GROUP   SITE

  • Hepatology. 2021;In press. On the mechanisms of biliary flux. Vartak N, Drasdo D, Geisler F, Itoh T, P J Oude Elferink R, van de Graaf SFJ, Chiang J, Keitel V, Trauner M, Jansen P, Hengstler JG. PubMed
  • Hepatology. 2020;71:1750-1765. Monoacylglycerol Lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis. Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Baumgartner M, A H O Ronda O, Verkade HJ, Stojakovic T, Scharnagl H, Habib A, Zimmermann R, Lotersztajn S, Trauner M. PubMed
  • Liver Int. 2020;40:1366-1377. Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice. Fuchs CD, Krivanec S, Steinacher D, Mlitz V, Wahlström A, Stahlman M, Claudel T, Scharnagl H, Stojakovic T, Marschall HU, Trauner M. PubMed
  • Contrast Media Mol Imaging. 2018;2018:8489709. Noninvasive monitoring of liver disease regression after Hepatitis C eradication using Gadoxetic acid-enhanced MRI. Haider L, Mandorfer M, Güngören Z, Reiberger T, Bastati N, Hodge JC, Chromy D, Trauner M, Herold C, Peck-Radosavljevic M, Ba-Ssalamah A. PubMed
  • J Lipid Res. 2018;59:1610-1619. Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice. Gautherot J, Claudel T, Cuperus F, Fuchs CD, Falguieres T, Trauner M. PubMed
  • J Hepatol. 2018;69:368-377.  Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. Pollheimer MJ, Racedo S, Mikels-Vigdal A, Marshall D, Bowlus C, Lackner C, Madl T, Karlsen TH, Hov JR, Lyman SK, Adamkewicz J, Smith V, Moreau E, Zollner G, Eide TJ, Stojakovic T, Scharnagl H, Gruber HJ, Stauber RE, Trauner M, Fickert P. PubMed
  • Abdom Radiol (NY). 2018;43:2963-2969. Imaging. [11C]acetate PET as a tool for diagnosis of liver steatosis. Nejabat M, Leisser A, Karanikas G, Wadsak W, Mitterhauser M, Mayerhöfer M, Kienbacher C, Trauner M, Hacker M, Haug AR. PubMed
  • Gut. 2018;67:1683-1691. Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids. Fuchs CD, Paumgartner G, Mlitz V, Kunczer V, Halilbasic E, Leditznig N, Wahlström A, Ståhlman M, Thüringer A, Kashofer K, Stojakovic T, Marschall HU, Trauner M. PubMed
  • Hepatology. 2018;In press. Na+-taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, Oude Elferink RPJ, van de Graaf SFJ. PubMed
  • Annu Rev Pathol. 2018;13:321-350. Recent insights into the pathogenesis of Nonalcoholic Fatty Liver Disease. Arab JP, Arrese M, Trauner M. PubMed
  • Oncotarget. 2017;8:57109-57120. Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M. PubMed
  • Mol Pharmacol. 2017;92:401-413. Molecular mechanism of taurocholate transport by the Bile Salt Export Pump, an ABC transporter associated with intrahepatic cholestasis. Sohail MI, Schmid D, Wlcek K, Spork M, Szakács G, Trauner M, Stockner T, Chiba P. PubMed
  • Invest Radiol. 2017;52:462-469. Imaging. Effects of portal hypertension on Gadoxetic Acid-enhanced liver Magnetic Resonance: diagnostic and prognostic implications. Asenbaum U, Ba-Ssalamah A, Mandorfer M, Nolz R, Furtner J, Reiberger T, Ferlitsch A, Kaczirek K, Trauner M, Peck-Radosavljevic M, Wibmer AG. PubMed
  • J Hepatol. 2017;67:549-558. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. PubMed
  • Hepatology. 2017;65:1393-1404. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. PubMed
  • Oncotarget. 2016;2016;7:86985-86998. Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease. Lemberger UJ, Fuchs C, Karer M, Haas S, Stojakovic T, Schöfer C, Marschall HU, Wrba F, Taketo MM, Egger G, Trauner M, Österreicher CH. PubMed
  • J Hepatol. 2017;66:95-101. Metabolic preconditioning protects BSEP/ABCB11-/- mice against cholestatic liver injury. Fuchs CD, Paumgartner G, Wahlström A, Schwabl P, Reiberger T, Leditznig N, Stojakovic T, Rohr-Udilova N, Chiba P, Marschall HU, Trauner M. PubMed
  • Hepatology. 2017;65:350-362. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. PubMed
  • J Magn Reson Imaging. 2017;45:646-659. Imaging. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, Herold CJ, Bashir MR, Van Beers BE. PubMed
  • Invest Radiol. 2016;51:728-734. Imaging. Assessment of orthotopic liver transplant graft survival on gadoxetic acid-enhanced magnetic resonance imaging using qualitative and quantitative parameters. Bastati N, Wibmer A, Tamandl D, Einspieler H, Hodge JC, Poetter-Lang S, Rockenschaub S, Berlakovich GA, Trauner M, Herold C, Ba-Ssalamah A. PubMed
  • J Pharm Sci. 2016;105:106-12. Imaging. Influence of 24-Nor-Ursodeoxycholic acid on hepatic disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography study in mice. Wanek T, Halilbasic E, Visentin M, Mairinger S, Römermann K, Stieger B, Kuntner C, Müller M, Langer O, Trauner M. PubMed
  • Radiology. 2015;277:104-13. Imaging. Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Ba-Ssalamah A, Antunes C, Feier D, Bastati N, Hodge JC, Stift J, Cipriano MA, Wrba F, Trauner M, Herold CJ, Caseiro-Alves F. PubMed
  • J Hepatol. 2015;62:S25-37.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. Beuers U, Trauner M, Jansen P, Poupon R. PubMed
  • Digestion. 2014;90:81-8. Alterations of canalicular ATP-binding cassette transporter expression in drug-induced liver injury. Zollner G, Thueringer A, Lackner C, Fickert P, Trauner M. PubMed
  • Drug Discov Today Technol. 2014;12:e87-94.  Pharmacological correction of misfolding of ABC proteins. Rudashevskaya EL, Stockner T, Trauner M, Freissmuth M, Chiba P. PubMed
  • Drug Metab Dispos. 2014;42:1423-31. Inflammatory bowel disease alters intestinal bile acid transporter expression. Jahnel J, Fickert P, Hauer AC, Högenauer C, Avian A, Trauner M. PubMed
  • Drug Metab Dispos. 2014;42:546-60. The role of canalicular ABC transporters in cholestasis. Cuperus FJ, Claudel T, Gautherot J, Halilbasic E, Trauner M. PubMed
  • Mol Aspects Med. 2014;37:57-76. Clinical application of transcriptional activators of bile salt transporters. Baghdasaryan A, Chiba P, Trauner M. PubMed
  • Digestion. 2012;86:244-9. Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans. Marschall HU, Wagner M, Zollner G, Fickert P, Silbert D, Gustafsson U, Sahlin S, Trauner M. PubMed

PubMed

Vienna, Austria

TRAUNER MICHAEL.jpg

Last update: October 2021